🔥POLCAGB Ph 3 neoadjuvant chemo vs neoadjuvant chemorads + chemo in locally adv GBC ➡️ closed at interim due to poor accrual 124 pts randomised ➡️ORR 74% vs 36% ➡️mOS 22mths vs 10ths Imp data - rads has a role! Nb 20% her2 amp in GBC- needs explored #ASCO25 ASCO OncoAlert

Presented at #ASCO25: In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial

📣#ASCO25 distilled by CancerTrialsIreland 🌈 hosted ISMO ☘️ webinar: Top 3 abstracts 📃 by tumor type✅ Single slide summaries of practice 🩻changing developments ✅ Insights from NEJM authors ✅ Trainee abroad 🍁 perspective ✅ Join Us 👇

Optimal approach in BR-PDAC/LAPC ✅starting with neoadjuvant therapy ❓is there a role for switch tx ?PAXG? ❓how do we incorporate CA19.9 dynamics ❓ what’s the best biomarker Fantastic talk from Bas Groot Koerkamp #PDAC #EAHPBA2025

Great overview of #PrecisionMedicine in #PDAC by Eileen M O’Reilly at ESMO - Eur. Oncology #ESMOGI25 If you missed it, please watch it 📺 🧬NGS important, with RNA for fusions 🫶KRAS 🤞🏻MTAP 👀Claudin 18.2 🤝Molecular Tumor Board-ESMO recomendations available #ESMOAmbassadors Ben Westphalen

Congrats to oncology trainee Mary O’Reilly presenting data from her PhD on early onset colorectal cancer at ESMO GI 2025 ESMO - Eur. Oncology Ray McDermott Grainne O'Kane St Vincent's University Hospital (SVUH)

Most viewed this week from JAMA Oncology: Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials. ja.ma/454REOi

According to a study co-led by researchers at MSK and published in Nature Medicine, a new vaccine shows encouraging early results as a potential ready-made treatment for patients with pancreatic or colorectal cancer. Unlike individualized cancer vaccines, which are tailored to

Hepatic metastases management: A comparative review of surgical resection, thermal ablation, and stereotactic body radiation therapy Eur J Cancer doi.org/10.1016/j.ejca… 🔎narrative review 👉multiple complementary options 👉Surgery most effective, but RFA & SBRT valid

Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patients - ESMO Gastrointestinal Oncology esmogastro.org/article/S2949-…

Revolution Medicines Daraxonrasib data in first line metastatic #PancreaticCancer - monotherapy & combination with Gemcitabine nab-paclitaxel. Even monotherapy ORRs and DCRs are impressive! Do you need the chemo? Grade 3 AEs go from 35% to 58%. RASOLUTE 303 will answer.

Great work Darren Cowzer Memorial Sloan Kettering Cancer Center on #cfDNA #biliarytractcancer published today in Journal of Clinical Oncology precision oncology. Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer | JCO Precision Oncology ascopubs.org/doi/10.1200/PO…

This week, we highlighted research by Jennifer J Knox, Grainne O'Kane, Dr. Amber Habowski, Mike Pishvaian, Eileen M O’Reilly, Brian Wolpin, Pugh Lab, David Tuveson, Dr. Elizabeth Jaffee, and others published in Journal of Clinical Oncology. Learn more: bit.ly/4naJmfz.

📢Biliary tract, HCC and pancreatic cancers oral abstracts in #ESMO25 ESMO - Eur. Oncology 👇 😍There are a lot of oral upper GI abstracts in #ESMO25. I am sure that some are practice-changing but all will give very important insights for practice! #cancer #oncology #GI #biliary

Looking forward to #HBP oral #ESMO25 ESMO - Eur. Oncology MSK Department of Medicine, honor to present re: #MET as a target.

MSK Pancreas team MSKCC Center for Pancreatic Cancer Research keeps growing with extraordinary talents! 좌청룡 우백호 Marc Hilmi Junmin Song, MD, MS Catherine O'Connor Michael & Anu & more - can’t wait to look back in 10 years and see what these amazing colleagues will have achieved. #AACRPan25 MSK Department of Medicine #PancSM #ATeam

🧬 Adjuvant & Neoadjuvant Immunotherapy in HCC - The Next Frontier! 🌟 🔹 Why It Matters? Half of all patients relapse after “curative” resection or ablation -time to move systemic therapy upfront! 💉 Neoadjuvant Highlights • Phase 2 data show MPR 20–42%, pCR 6–32% with PD-1 ±

🔥off the press🔥 Navigating second-line therapy after immunotherapy in advanced HCC JHEP Reports doi.org/10.1016/j.jhep… 👉Multiple options in first and second line 😅Our thoughts on how to best sequence ESMO - Eur. Oncology EASL Education ILCA

🇮🇪 More Irish research in the spotlight at #ESMO25 poster session today! 🌍 Hailey K. Carroll St Vincent's University Hospital (SVUH) - spotlighting how climate and environmental factors will shape Ireland’s next cancer strategy. 💉 Zain Ul Abedin Bon Secours Cork Cancer Centre Cancer Research @UCC - exploring acupuncture to improve

Pancreas Wars: A New Hope ⚔️✨ Had a blast on stage with this rockstar panel at #ESMO25. Ben Westphalen Grainne O'Kane Sara Monica Pancreas is heating up 🔥next wave of precision oncology Just hold my drink and watch these rebels jam. 🎸 #PancreasWars #PrecisionOncology #TeamScience